Product Availability Update for Gammaplex Immune Globulin
Gammaplex, an immune globulin, is indicated to treat chronic immune thrombocytopenic purpura (ITP) and primary humoral immunodeficiency.
Primary Immune Deficiency
Gammaplex 10% Gets FDA Approval
Bio Products Laboratory announced that the Food and Drug Administration (FDA) has approved Gammaplex 10% (immune globulin intravenous [human], 10% liquid) for the treatment of primary immunodeficiency (PI) and chronic immune thrombocytopenic purpura (ITP) in adults.
Cuvitru Now Available for Primary Immunodeficiency
Shire announced the launch of Cuvitru (immune globulin subcutaneous [human], 20% solution) indicated as replacement therapy for primary humoral immunodeficiency (PI) in patients aged ≥2 years.
Study Examines Rubella Persistence Post-Vaccine in Immunodeficient Patients
Some patients with primary immunodeficiency disorders may be at risk for rubella virus infection and possible serious skin inflammation after receiving the rubella vaccine, a study published in the Journal of Allergy and Clinical Immunology has found.
Cuvitru Approved for Primary Immunodeficiency
Shire announced that the Food and Drug Administration (FDA) has approved Cuvitru (immune globulin subcutaneous [human]) 20% solution for the treatment of primary immunodeficiency in patients aged ≥2 years.
FDA Accepts IVIG-SN BLA for Primary Immunodeficiency
Green Cross announced that the Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for IVIG-SN (human normal immunoglobulin G), for the treatment of primary immunodeficiency diseases (PID).
New IVIG BLA Submitted for Primary Immunodeficiency
Green Cross announced that it has submitted its Biologics License Application (BLA) to the FDA for IVIG-SN (human normal immunoglobulin G) for the treatment of primary immunodeficiency diseases (PID).
Why Organ Transplant Patients May Be at Lower Risk for Alzheimer’s Disease
A treatment taken by organ transplant patients to prevent organ rejection may help protect against Alzheimer’s disease.
Gene Tx May Benefit Wiskott-Aldrich Sx in Children, Teens
Gene therapy may benefit children and teens with Wiskott-Aldrich syndrome, a rare immunodeficiency caused by mutations in the WAS gene.
![HIZENTRA (immune globulin [human]) 20% liquid by CSL Behring](https://www.empr.com/wp-content/uploads/sites/7/2018/12/hizentra_91291.jpg)
Flexible Dosing Option for Hizentra Approved
CSL Behring announced that the Food and Drug Administration (FDA) has approved a new dosing option for Hizentra (immune serum globulin [human]) 0.2mg/mL (20%) Liquid to include treatment at regular intervals from daily to biweekly in patients with primary immunodeficiency.
